Company intelligence / Profile preview

Origo Enterprises

Ownership: Private
Development stage: Other

Overview

Origo Enterprises provides pharmaceutical consultancy services focused on formulation development, analytical method development, regulatory strategy, bioavailability/bioequivalence study support, cGMP compliance audits, dossier preparation for US/EU markets (including ANDA/NDA filings), outsourcing of manufacturing/testing/clinical studies, and strategic advisory for pharma companies. Their expertise covers generic dosage forms including injectables, ophthalmic products, tablets/capsules/semi-solids/NDDS. They also offer guidance on regulatory submissions to agencies such as USFDA and EMA.

Industry: Consulting

Beyond the preview

Go deeper on Origo Enterprises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Origo Enterprises.

Explore the full profile